Loading...

Davide Verotta, PhD

Title(s)Professor Emeritus, Clinical Pharmacy
SchoolSchool of Pharmacy
AddressLocation Required
Varies CA 00000
Phone415-476-1556
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    School of Pharmacy, UCSF2005Dean's Recognition for Excellence in Teaching

    Collapse Overview 
    Collapse Overview
    Dr. Davide Verotta’s main research interests are in pharmacokinetics and pharmacodynamics (PKPD) and mathematical statistical (MS) modeling. In PKPD, his main areas of interest are: mechanistic modeling (where prior knowledge about parts of a PKPD system is embedded in the model describing it); the development of empirical models (where no prior knowledge is embedded in the model) to analyze, simulate and control; population PKPD modeling with particular regard to empirical methods for population data analysis. In MS modeling, his main interests are in linear and non-linear system analysis, control, and experimental design. He is involved in collaborative research with scientists and different investigators in PKPD and clinical therapy (notably HIV therapy) modeling. Additional areas of investigation are the use of Bayesian methods, in particular applied to pharmacogenomics and mechanistic modeling, fractional differential equations, and applications of functional data analysis to population PKPD.

    Collapse Research 
    Collapse Research Activities and Funding
    Modeling Complex Pharmacokinetics and Pharmacodynamics
    NIH/NIAID R01AI050587Sep 30, 2002 - May 31, 2013
    Role: Principal Investigator
    MODELS FOR BIOLOGICAL DATA RELEVANT TO HEALTH CARE
    NIH/NIGMS R29GM051197Sep 1, 1995 - Aug 31, 2001
    Role: Principal Investigator
    Pharmacokinetic / Pharmacodynamic Data Analysis
    NIH/NIGMS R01GM026676Sep 1, 1979 - Aug 31, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. J Clin Endocrinol Metab. 2018 09 01; 103(9):3278-3288. Schwartz JB, Gallagher JC, Jorde R, Berg V, Walsh J, Eastell R, Evans AL, Bowles S, Naylor KE, Jones KS, Schoenmakers I, Holick M, Orwoll E, Nielson C, Kaufmann M, Jones G, Bouillon R, Lai J, Verotta D, Bikle D. PMID: 29955795.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    2. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124. Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. PMID: 29854560.
      View in: PubMed   Mentions:
    3. Mathematical Modeling of Biofilm Structures Using COMSTAT Data. Comput Math Methods Med. 2017; 2017:7246286. Verotta D, Haagensen J, Spormann AM, Yang K. PMID: 29422943.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    4. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. J Antimicrob Chemother. 2017 Dec 01; 72(12):3357-3365. Haagensen J, Verotta D, Huang L, Engel J, Spormann AM, Yang K. PMID: 28961810.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    5. New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms. Antimicrob Agents Chemother. 2015 Jul; 59(7):4074-81. Haagensen JA, Verotta D, Huang L, Spormann A, Yang K. PMID: 25918138.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. PMID: 24861874.
      View in: PubMed   Mentions: 4     Fields:    
    7. Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J Perinatol. 2013 Oct; 33(10):778-82. Frymoyer A, Lee S, Bonifacio SL, Meng L, Lucas SS, Guglielmo BJ, Sun Y, Verotta D. PMID: 23702622.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    8. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy. 2013 Jul; 33(7):718-26. Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ. PMID: 23553582.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    9. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013 Feb; 75(2):463-75. Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. PMID: 22765258.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    10. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT. PMID: 22301417.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    11. A method to quantify illicit intake of drugs from urine: methamphetamine. J Pharmacol Exp Ther. 2011 Jul; 338(1):31-6. Li L, Galloway GP, Verotta D, Everhart ET, Baggott MJ, Coyle JR, Lopez JC, Mendelson J. PMID: 21450932.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    12. Fractional dynamics pharmacokinetics-pharmacodynamic models. J Pharmacokinet Pharmacodyn. 2010 Jun; 37(3):257-76. Verotta D. PMID: 20455076.
      View in: PubMed   Mentions: 8     Fields:    
    13. Fractional compartmental models and multi-term Mittag-Leffler response functions. J Pharmacokinet Pharmacodyn. 2010 Apr; 37(2):209-15; discussion 217-20. Verotta D. PMID: 20405313.
      View in: PubMed   Mentions: 8     Fields:    
    14. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther. 2009 Nov; 86(5):497-502. Schwartz JB, Verotta D. PMID: 19571802.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. Eur J Pharm Sci. 2009 Mar 02; 36(4-5):421-32. Perger L, Rentsch KM, Kullak-Ublick GA, Verotta D, Fattinger K. PMID: 19084595.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain. J Pharmacokinet Pharmacodyn. 2008 Feb; 35(1):69-83. Kshirsagar S, Gear R, Levine J, Verotta D. PMID: 17943420.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Reversible jump Markov chain Monte Carlo for deconvolution. J Pharmacokinet Pharmacodyn. 2007 Jun; 34(3):263-87. Kang D, Verotta D. PMID: 17221310.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. J Pharmacokinet Pharmacodyn. 2007 Feb; 34(1):35-55. Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. PMID: 17004125.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    19. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn. 2006 Aug; 33(4):519-42. Labbé L, Verotta D. PMID: 16786410.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    20. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006 Jun; 33(3):227-79. Csajka C, Verotta D. PMID: 16404503.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    21. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther. 2006 Jan; 79(1):114-24. Kang D, Verotta D, Schwartz JB. PMID: 16413246.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Sample size computations for PK/PD population models. J Pharmacokinet Pharmacodyn. 2005 Dec; 32(5-6):685-701. Kang D, Schwartz JB, Verotta D. PMID: 16284914.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    23. The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption. Pharm Res. 2005 Aug; 22(8):1227-35. Csajka C, Drover D, Verotta D. PMID: 16078132.
      View in: PubMed   Mentions: 12     Fields:    
    24. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol. 2005 Mar; 59(3):355-64. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D. PMID: 15752382.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    25. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Br J Clin Pharmacol. 2005 Mar; 59(3):335-45. Csajka C, Haller CA, Benowitz NL, Verotta D. PMID: 15752380.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. J Pharmacol Exp Ther. 2005 May; 313(2):647-57. Csajka C, Imbimbo BP, Piccinno A, Dostert P, Verotta D. PMID: 15671203.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Stat Med. 2004 Aug 30; 23(16):2551-66. Kang D, Schwartz JB, Verotta D. PMID: 15287084.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004 May; 127(Pt 5):1047-60. Valle M, Price RW, Nilsson A, Heyes M, Verotta D. PMID: 15013955.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    29. Volterra series in pharmacokinetics and pharmacodynamics. J Pharmacokinet Pharmacodyn. 2003 Oct; 30(5):337-62. Verotta D. PMID: 14977164.
      View in: PubMed   Mentions: 2     Fields:    
    30. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther. 2003 Jan; 73(1):31-40. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. PMID: 12545141.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    31. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002 Oct; 97(4):827-36. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D. PMID: 12357147.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    32. Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum. J Pharmacokinet Pharmacodyn. 2002 Aug; 29(4):383-402. Pitsiu M, Gries JM, Benowitz N, Gourlay SG, Verotta D. PMID: 12518710.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    33. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math Biosci. 2002 Apr; 176(2):163-83. Verotta D, Schaedeli F. PMID: 11916507.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    34. Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation. J Pharmacokinet Pharmacodyn. 2002 Feb; 29(1):49-66. Schaedeli F, Pitsiu M, Benowitz NL, Gourlay SG, Verotta D. PMID: 12194535.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn. 2001 Aug; 28(4):343-62. Lu J, Gries JM, Verotta D, Sheiner LB. PMID: 11677931.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    36. A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J Pharm Sci. 2001 Jun; 90(6):702-12. Pitsiu M, Sathyan G, Gupta S, Verotta D. PMID: 11357173.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    37. Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data. J Biopharm Stat. 2000 Aug; 10(3):383-98. Gries JM, Verotta D. PMID: 10959918.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    38. Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. Eur J Clin Pharmacol. 2000 Jul; 56(4):305-10. Fattinger K, Benowitz NL, Jones RT, Verotta D. PMID: 10954344.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    39. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology. 2000 Mar; 92(3):821-32. Kindler CH, Verotta D, Gray AT, Gropper MA, Yost CS. PMID: 10719961.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    40. Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther. 1999 Apr; 289(1):371-7. Gries JM, Munafo A, Porchet HC, Verotta D. PMID: 10087026.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    41. A general solution for nonparametric control of a linear system using computer-controlled infusion pumps. IEEE Trans Biomed Eng. 1999 Jan; 46(1):44-50. Verotta D. PMID: 9919825.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    42. Characterizing the variability of system kernel and input estimates. Ann Biomed Eng. 1998 Sep-Oct; 26(5):870-82. Verotta D. PMID: 9779960.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J Pharmacokinet Biopharm. 1998 Aug; 26(4):471-92. Park K, Verotta D, Gupta SK, Sheiner LB. PMID: 10214563.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    44. Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems. J Pharmacol Exp Ther. 1998 May; 285(2):457-63. Gries JM, Benowitz N, Verotta D. PMID: 9580583.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    45. Passive versus electrotransport-facilitated transdermal absorption of ketorolac. Clin Pharmacol Ther. 1998 Mar; 63(3):303-15. Park K, Verotta D, Gupta SK, Sheiner LB. PMID: 9542474.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov; 41(11):2433-8. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF. PMID: 9371346.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    47. Age effects on interrelationships between lung volume and heart rate during standing. Am J Physiol. 1997 11; 273(5):H2128-34. Stanley G, Verotta D, Craft N, Siegel RA, Schwartz JB. PMID: 9374744.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    48. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov; 41(11):2428-32. Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF. PMID: 9371345.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    49. A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm. 1997 Oct; 25(5):615-42. Park K, Verotta D, Blaschke TF, Sheiner LB. PMID: 9679225.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997 Jun; 281(3):1238-46. Fattinger K, Verotta D, Benowitz NL. PMID: 9190859.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    51. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Clin Pharmacol Ther. 1997 Jan; 61(1):70-82. Gries JM, Troconiz IF, Verotta D, Jacobson M, Sheiner LB. PMID: 9024175.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    52. A general framework for non-parametric subject-specific and population deconvolution methods for in vivo-in vitro correlation. Adv Exp Med Biol. 1997; 423:43-52. Verotta D. PMID: 9269482.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    53. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther. 1996 Oct; 60(4):385-95. Gries JM, Benowitz N, Verotta D. PMID: 8873686.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    54. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol. 1996 Oct; 271(4 Pt 1):E775-87. Fattinger KE, Verotta D, Porchet HC, Munafo A, Le Cotonnec JY, Sheiner LB. PMID: 8897868.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    55. Age and autonomic effects on interrelationships between lung volume and heart rate. Am J Physiol. 1996 May; 270(5 Pt 2):H1833-40. Stanley G, Verotta D, Craft N, Siegel RA, Schwartz JB. PMID: 8928893.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    56. A descriptive tool to characterize nonlinear kinetics, with applications to meperidine and lidocaine. J Pharm Sci. 1996 Apr; 85(4):362-8. Gries JM, Upton R, Huang YF, Verotta D. PMID: 8901069.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    57. Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Crit Rev Biomed Eng. 1996; 24(2-3):73-139. Verotta D. PMID: 9108983.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    58. A new method to explore the distribution of interindividual random effects in non-linear mixed effects models. Biometrics. 1995 Dec; 51(4):1236-51. Fattinger KE, Sheiner LB, Verotta D. PMID: 8589220.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    59. A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples. J Pharmacokinet Biopharm. 1995 Dec; 23(6):581-610. Fattinger KE, Verotta D. PMID: 8733948.
      View in: PubMed   Mentions: 10     Fields:    
    60. A nonparametric subject-specific population method for deconvolution: II. External validation. J Pharmacokinet Biopharm. 1995 Dec; 23(6):611-34. Fattinger KE, Verotta D. PMID: 8733949.
      View in: PubMed   Mentions: 5     Fields:    
    61. Estimating bioavailability when clearance changes in time: the effect of model misspecification. Clin Pharmacol Ther. 1995 Nov; 58(5):595-600. Fattinger KE, Verotta D. PMID: 7586955.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. Further notes on physiologic indirect response models. Clin Pharmacol Ther. 1995 Aug; 58(2):238-40. Sheiner LB, Verotta D. PMID: 7648775.
      View in: PubMed   Mentions: 5     Fields:    
    63. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm. 1995 Feb; 23(1):1-4. Verotta D, Sheiner LB. PMID: 8576839.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    64. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences. Br J Clin Pharmacol. 1994 Nov; 38(5):389-400. Gumbleton M, Oie S, Verotta D. PMID: 7893578.
      View in: PubMed   Mentions: 6     Fields:    
    65. Semiparametric models for antagonistic drug interactions. J Appl Physiol (1985). 1994 May; 76(5):2224-33. Troconiz IF, Sheiner LB, Verotta D. PMID: 7914889.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    66. Estimation and model selection in constrained deconvolution. Ann Biomed Eng. 1993 Nov-Dec; 21(6):605-20. Verotta D. PMID: 8116913.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    67. Two constrained deconvolution methods using spline functions. J Pharmacokinet Biopharm. 1993 Oct; 21(5):609-36. Verotta D. PMID: 8145134.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    68. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther. 1993 May; 265(2):690-8. Schwartz JB, Troconiz IF, Verotta D, Liu S, Capili H. PMID: 8496816.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    69. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology. 1992 Oct; 77(4):646-55. Cahalan MK, Hashimoto Y, Aizawa K, Verotta D, Ionescu P, Balea M, Eger EI, Benet LZ, Ehrenfeld WK, Goldstone J. PMID: 1416161.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    70. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992 Oct; 20(5):511-28. Mandema JW, Verotta D, Sheiner LB. PMID: 1287200.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    71. Comparing responses when each response is a curve. Am J Physiol. 1992 Jul; 263(1 Pt 2):R206-14. Verotta D, Sheiner LB. PMID: 1636790.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    72. Reversal of neuromuscular blockade in humans by neostigmine and edrophonium: a mathematical model. J Pharmacokinet Biopharm. 1991 Dec; 19(6):713-29. Verotta D, Kitts J, Rodriguez R, Coldwell J, Miller RD, Sheiner LB. PMID: 1687690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Semiparametric analysis of non-steady-state pharmacodynamic data. J Pharmacokinet Biopharm. 1991 Dec; 19(6):691-712. Verotta D, Sheiner LB. PMID: 1815048.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    74. Mean time parameters for generalized physiological flow models (semihomogeneous linear systems). J Pharmacokinet Biopharm. 1991 Jun; 19(3):319-31. Verotta D, Sheiner LB, Beal SL. PMID: 1875285.
      View in: PubMed   Mentions: 3     Fields:    
    75. An application of the D-optimal criterion to define the experimental design for a particular class of semi-parametric models. Comput Methods Programs Biomed. 1990 Nov; 33(3):181-7. Verotta D. PMID: 2279391.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    76. Comments on two recent deconvolution methods. J Pharmacokinet Biopharm. 1990 Oct; 18(5):483-9; discussion 489-99. Verotta D. PMID: 2266499.
      View in: PubMed   Mentions: 5     Fields:    
    77. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology. 1990 May; 72(5):865-73. Björkman S, Stanski DR, Verotta D, Harashima H. PMID: 2339802.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    78. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions. J Pharmacol Exp Ther. 1989 Dec; 251(3):1032-8. Schwartz JB, Verotta D, Sheiner LB. PMID: 2600802.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    79. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther. 1989 Oct; 46(4):408-19. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, Giacomini KM. PMID: 2791444.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    80. A semiparametric approach to physiological flow models. J Pharmacokinet Biopharm. 1989 Aug; 17(4):463-91. Verotta D, Sheiner LB, Ebling WF, Stanski DR. PMID: 2614682.
      View in: PubMed   Mentions: 10     Fields:    
    81. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol. 1989 Apr; 256(4 Pt 2):R1005-10. Verotta D, Beal SL, Sheiner LB. PMID: 2705568.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    82. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci. 1988 Sep; 77(9):784-9. Imbimbo BP, Imbimbo E, Daniotti S, Verotta D, Bassotti G. PMID: 2976092.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    83. D-optimal design applied to binding saturation curves of an enkephalin analog in rat brain. Life Sci. 1988; 42(6):735-43. Verotta D, Petrillo P, La Regina A, Rocchetti M, Tavani A. PMID: 2828802.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    84. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm. Comput Appl Biosci. 1987 Nov; 3(4):345-9. Verotta D, Sheiner LB. PMID: 2898970.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    85. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm. 1987 Jun; 15(3):241-53. Schüttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D, Sheiner LB. PMID: 3668802.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    Davide's Networks
    Concepts (327)
    Derived automatically from this person's publications.
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _